10-Q quarterly report · filed Nov 9, 2026

Annexon, Inc. (ANNX) Q3 2026 10-Q Quarterly Report

Short answer

Annexon, Inc. (ANNX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$51M
+6.7% YoY · +7.5% QoQ
EPS (diluted)
−$0.25
+32.4% YoY · +7.4% QoQ

Source: XBRL data from the Annexon, Inc. (ANNX) Q3 2026 10-Q on SEC EDGAR. USD.

Annexon, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • No product revenue; quarterly net loss $51.2M vs $54.9M YoY, down 7%
  • R&D expenses $41.4M vs $49.7M YoY, down 17%, driven by lower contract manufacturing
  • G&A expenses $10.9M vs $7.3M YoY, up 49%, worst cost trend versus R&D
  • Cash and investments $213.4M; operating cash use $143.5M through nine months vs $140.4M YoY
  • $50.0M term loan funded; cash runway into 2028, with substantial additional financing required

Risk Factors

  • New financing risk: July 2026 Loan Agreement added $50.0 million debt, with floating interest of at least 7.60% and substantially all assets pledged
  • Most material clinical update: ARCHER II expanded in August 2026 with Month 24 dual primary endpoint and open-label extension, increasing duration, complexity and funding needs
  • Regulatory risk: FDA indicated tanruprubart’s foreign-data generalizability package may require additional GBS patient data before BLA approval
  • Competitive risk: Two approved GA products may limit vonaprument adoption if it reaches commercialization
  • Liquidity risk: $213.4 million in cash and short-term investments expected to fund operations into 2028, but expanded Phase 3 work may require earlier financing

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Annexon, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.